Biomarkers associated with early stages of kidney disease in adolescents with type 1 diabetes.
Adolescent
Adult
Age Factors
Biomarkers
/ blood
Child
Cohort Studies
Cystatin C
/ blood
Diabetes Mellitus, Type 1
/ blood
Diabetic Nephropathies
/ blood
Fibroblast Growth Factor-23
Fibroblast Growth Factors
/ blood
Glomerular Filtration Rate
Humans
Middle Aged
Osteopontin
/ blood
Trefoil Factor-3
/ blood
Young Adult
beta 2-Microglobulin
/ blood
GFR
adolescents
biomarkers
complications
kidney disease
Journal
Pediatric diabetes
ISSN: 1399-5448
Titre abrégé: Pediatr Diabetes
Pays: Denmark
ID NLM: 100939345
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
22
03
2020
revised:
18
05
2020
accepted:
17
07
2020
pubmed:
13
8
2020
medline:
19
11
2021
entrez:
13
8
2020
Statut:
ppublish
Résumé
To identify biomarkers of renal disease in adolescents with type 1 diabetes (T1D) and to compare findings in adults with T1D. Twenty-five serum biomarkers were measured, using a Luminex platform, in 553 adolescents (median [interquartile range] age: 13.9 [12.6, 15.2] years), recruited to the Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial. Associations with baseline and final estimated glomerular filtration rate (eGFR), rapid decliner and rapid increaser phenotypes (eGFR slopes <-3 and > 3 mL/min/1.73m In the adolescent cohort, baseline eGFR was negatively associated with trefoil factor-3, cystatin C, and beta-2 microglobulin (B2M) (B coefficient[95%CI]: -0.19 [-0.27, -0.12], P = 7.0 × 10 In this young population with T1D and high rates of hyperfiltration, osteopontin was the most consistent biomarker associated with prospective changes in eGFR. FGF-23 was associated with eGFR increases, whereas trefoil factor-3, cystatin C, and B2M were associated with baseline eGFR.
Substances chimiques
B2M protein, human
0
Biomarkers
0
CST3 protein, human
0
Cystatin C
0
FGF23 protein, human
0
SPP1 protein, human
0
TFF3 protein, human
0
Trefoil Factor-3
0
beta 2-Microglobulin
0
Osteopontin
106441-73-0
Fibroblast Growth Factors
62031-54-3
Fibroblast Growth Factor-23
7Q7P4S7RRE
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1322-1332Subventions
Organisme : Juvenile Diabetes Research Foundation
ID : 1-SRA-2016-333-M-R
Pays : United States
Organisme : British Heart Foundation
Pays : United Kingdom
Organisme : Chief Scientist Office
Pays : United Kingdom
Informations de copyright
© 2020 The Authors. Pediatric Diabetes published by John Wiley & Sons Ltd.
Références
Forbes JM, Fotheringham AK. Vascular complications in diabetes: old messages, new thoughts. Diabetologia. 2017;60(11):2129-2138.
Bjerg L, Hulman A, Carstensen B, Charles M, Witte DR, Jørgensen ME. Effect of duration and burden of microvascular complications on mortality rate in type 1 diabetes: an observational clinical cohort study. Diabetologia. 2019;62(4):633-643.
Amin R, Turner C, van Aken S, et al. The relationship between microalbuminuria and glomerular filtration rate in young type 1 diabetic subjects: the Oxford regional prospective study. Kidney Int. 2005;68(4):1740-1749.
Krolewski AS, Gohda T, Niewczas MA. Progressive renal decline as the major feature of diabetic nephropathy in type 1 diabetes. Clin Exp Nephrol. Springer-Verlag Tokyo. 2014;18(4):571-583.
Dunger DB, Schwarze CP, Cooper JD, et al. Can we identify adolescents at high risk for nephropathy before the development of microalbuminuria? Diabet Med. 2007;24(2):131-136.
Marcovecchio ML, Chiesa ST, Armitage J, et al. Renal and cardiovascular risk according to tertiles of urinary albumin-to-Creatinine ratio: the adolescent type 1 diabetes cardio-renal intervention trial (AdDIT). Diabetes Care. 2018;41(9):1963-1969.
Tonneijck L, Muskiet MHA, Smits MM, et al. Glomerular Hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol. 2017;28(4):1023-1039.
Lovshin JA, Škrtić M, Bjornstad P, et al. Hyperfiltration, urinary albumin excretion, and ambulatory blood pressure in adolescents with type 1 diabetes mellitus. Am J Physiol Renal Physiol. 2018;314(4):F667-F674.
Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia. 2009;52(4):691-697.
Colhoun HM, Marcovecchio ML. Biomarkers of diabetic kidney disease. Diabetologia. 2018;61(5):996-1011.
Colombo M, Valo E, McGurnaghan SJ, et al. Biomarker panels associated with progression of renal disease in type 1 diabetes. Diabetologia. 2019;62(9):1616-1627.
Marcovecchio ML, Chiesa ST, Bond S, et al. ACE inhibitors and statins in adolescents with type 1 diabetes. N Engl J Med. 2017;377(18):1733-1745.
Marcovecchio ML, Woodside J, Jones T, et al. Adolescent type 1 diabetes cardio-renal intervention trial (AdDIT): urinary screening and baseline biochemical and cardiovascular assessments. Diabetes Care. 2014;37(3):805-813.
Marcovecchio ML, Dalton RN, Turner C, et al. Symmetric dimethylarginine, an endogenous marker of glomerular filtration rate, and the risk for microalbuminuria in young people with type 1 diabetes. Arch Dis Child. 2010;95(2):119-124.
Donadio C, Lucchesi A, Ardini M, Giordani R. Cystatin C, beta 2-microglobulin, and retinol-binding protein as indicators of glomerular filtration rate: comparison with plasma creatinine. J Pharm Biomed Anal. 2001;24(5-6):835-842.
Colombo M, Looker HC, Farran B, et al. Serum kidney injury molecule 1 and β2-microglobulin perform as well as larger biomarker panels for prediction of rapid decline in renal function in type 2 diabetes. Diabetologia. 2019;62(1):156-168.
Kim MK, Yun K-J, Chun HJ, et al. Clinical utility of serum beta-2-microglobulin as a predictor of diabetic complications in patients with type 2 diabetes without renal impairment. Diabetes Metab. 2014;40(6):459-465.
Foster MC, Inker LA, Hsu C, et al. Filtration markers as predictors of ESRD and mortality in southwestern American Indians with type 2 diabetes. Am J Kidney Dis. 2015;66(1):75-83.
Mohammadi-Shemirani P, Sjaarda J, et al. A Mendelian randomization-based approach to identify early and sensitive diagnostic biomarkers of disease. Clin Chem. 2018;65(3):427-436.
Icer MA, Gezmen-Karadag M. The multiple functions and mechanisms of osteopontin. Clin Biochem. 2018;59:17-24.
Kase S, Yokoi M, Saito W, et al. Increased osteopontin levels in the vitreous of patients with diabetic retinopathy. Ophthalmic Res. 2007;39(3):143-147.
Minoretti P, Falcone C, Calcagnino M, et al. Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur Heart J. 2006;27(7):802-807.
Gordin D, Forsblom C, Panduru NM, et al. Osteopontin is a strong predictor of incipient diabetic nephropathy, cardiovascular disease, and all-cause mortality in patients with type 1 diabetes. Diabetes Care. 2014;37(9):2593-2600.
Abo El-Asrar M, Ismail EAR, Thabet RA, Kamel AS, NehmedAllah S. Osteopontin as a marker of vasculopathy in pediatric patients with type 1 diabetes mellitus: relation to vascular structure. Pediatr Diabetes. 2018;19(6):1107-1115.
Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum Cystatin C alone and in combination with serum Creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis. 2008;51(3):395-406.
Vervloet M. Renal and extrarenal effects of fibroblast growth factor 23. Nat Rev Nephrol. 2019;15(2):109-120.
Titan SM, Zatz R, Graciolli FG, et al. FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin J Am Soc Nephrol. 2011;6(2):241-247.
Farías-Basulto A, Martínez-Ramírez HR, Gómez-García EF, et al. Circulating levels of soluble Klotho and fibroblast growth factor 23 in diabetic patients and its association with early nephropathy. Arch Med Res. 2018;49(7):451-455.
Akbar T, McGurnaghan S, Palmer CNA, et al. Cohort profile: Scottish diabetes research network type 1 bioresource study (SDRNT1BIO). Int J Epidemiol. 2017;46(3):796-796i.